Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Following Single Subcutaneous Injection in Healthy Adult Participants
Conditions
Interventions
GB18 injection
Placebo
Locations
1
China
Beijing GoBroad Hospital
Beijing, Beijing Municipality, China
Start Date
October 28, 2025
Primary Completion Date
January 20, 2026
Completion Date
April 20, 2026
Last Updated
November 19, 2025
NCT07072728
NCT07033026
NCT06898255
NCT01614990
NCT04208334
NCT04127981
Lead Sponsor
Shenzhen Kexing Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions